ThromboGenics Announces Protocol Amendment to Phase II CIRCLE Trial Evaluating THR-409 (ocriplasmin) in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

23 Dec 2016

Leuven - ThromboGenics NV today announced that the protocol of the Phase II CIRCLE Trial Evaluating Multiple Doses of THR-409 to induce a Total Posterior Vitreous Detachment in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) has been amended.

The changes will allow inclusion of patients with less severe non-proliferative diabetic retinopathy (ETDRS level 43A - 47A). This will result in a broader patient pool for the study to recruit from.

The amended study, which focuses on assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR, is now expected to enroll approximately 115 patients.